CD38 and autoimmune thrombocytopenic purpura: Its safety and efficiency will be assessed in ITP (NCT04703621), as will another anti-CD38 antibody, mezagitamab (TAK-079, NCT04278924), a fully human IgG1 that has already shown its safety in phase 1 study, either intravenously and subcutaneously [97].